What is the guideline‑directed medical therapy for an adult with heart failure with reduced ejection fraction (left ventricular ejection fraction ≤40%)?

Guideline-Directed Medical Therapy for HFrEF (LVEF ≤40%)

All adults with HFrEF (LVEF ≤40%) should receive simultaneous initiation of four foundational medication classes—ARNI (or ACE-I/ARB), evidence-based beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor—started at low doses and rapidly uptitrated to target doses, which reduces 2-year mortality by approximately 73% compared to no treatment. 1

Core Four-Pillar Pharmacotherapy

1. Renin-Angiotensin System Inhibition

• Sacubitril/valsartan (ARNI) is the preferred first-line agent over ACE inhibitors or ARBs, providing ≥20% mortality reduction versus the 5-16% reduction seen with ACE-I/ARB alone 1, 2
• Start sacubitril/valsartan 24/26 mg (or 49/51 mg) twice daily; target 97/103 mg twice daily 1
• Require a strict 36-hour washout period when switching from ACE inhibitor to ARNI to avoid angioedema 1
• If ARNI is not tolerated or available, use ACE inhibitors (e.g., enalapril 2.5-5 mg twice daily, target 10-20 mg twice daily) or ARBs (e.g., losartan 25-50 mg daily, target 150 mg daily) 3, 1
• ACE inhibitors are recommended for all patients with current or prior symptoms of HF and reduced LVEF unless contraindicated 3

2. Evidence-Based Beta-Blockers

• Only three beta-blockers have proven mortality benefit in HFrEF: carvedilol, metoprolol succinate, and bisoprolol—each providing ≥20% mortality reduction and reducing sudden cardiac death 3, 1, 2
• Carvedilol: start 3.125 mg twice daily; target 25-50 mg twice daily 1
• Metoprolol succinate (not tartrate): start 12.5-25 mg daily; target 200 mg daily 1
• Bisoprolol: start 1.25 mg daily; target 10 mg daily 1
• Beta-blockers should be initiated in clinically stable patients after volume optimization and discontinuation of IV diuretics, vasodilators, and inotropes 3, 1

3. Mineralocorticoid Receptor Antagonists (MRAs)

• Spironolactone or eplerenone provide ≥20% mortality reduction and reduce sudden cardiac death 3, 1, 2
• Start spironolactone 12.5-25 mg daily; target 50 mg daily 3, 1
• Start eplerenone 25 mg daily; target 50 mg daily 1
• Eplerenone avoids the 5.7% higher rate of gynecomastia seen with spironolactone 1
• Require eGFR >30 mL/min/1.73 m² and potassium <5.0 mEq/L before initiation 1

4. SGLT2 Inhibitors

• Dapagliflozin 10 mg daily or empagliflozin 10 mg daily provide significant mortality benefit regardless of diabetes status 1, 2
• No dose titration required; benefits occur within weeks of initiation 1
• Minimal blood pressure, heart rate, or potassium effects, making them ideal for immediate initiation 1
• Can be used if eGFR ≥30 mL/min/1.73 m² for empagliflozin or ≥20 mL/min/1.73 m² for dapagliflozin 1

Simultaneous Initiation Strategy

• Start all four medication classes simultaneously at low initial doses rather than sequential initiation, as this addresses the treatment gap where <25% of eligible patients receive all agents concurrently and only 1% reach target doses 1
• Uptitrate one drug at a time every 1-2 weeks using small increments until target or maximally tolerated dose is achieved 1
• Prioritize SGLT2 inhibitor and MRA first (minimal BP effects), then beta-blocker (if heart rate >60 bpm), then ARNI/ACE-I/ARB 1
• Check blood pressure, renal function, and electrolytes 1-2 weeks after each dose increment 1

Diuretics for Volume Management

• Loop diuretics are essential for congestion control but do not reduce mortality 3, 1
• Furosemide: start 20-40 mg once or twice daily; maximum 600 mg daily 3
• Torsemide: start 10-20 mg once daily; maximum 200 mg daily 3
• Bumetanide: start 0.5-1.0 mg once or twice daily; maximum 10 mg daily 3
• Titrate diuretic dose to achieve euvolemia (no edema, no orthopnea, no jugular venous distension), then use the lowest dose that maintains this state 1

Special Clinical Scenarios

Low Blood Pressure (SBP 80-100 mmHg)

• Never withhold GDMT for asymptomatic hypotension when perfusion is adequate; patients with adequate organ perfusion can safely tolerate SBP 80-100 mmHg 1
• Start SGLT2 inhibitor and MRA first (minimal BP impact), then add beta-blocker if heart rate >60 bpm, then add ARNI at very low dose 1
• Discontinue non-essential BP-lowering medications (alpha-blockers for benign prostatic hyperplasia, unnecessary antihypertensives) 1
• Evaluate for reversible causes: dehydration, infection, acute illness 1
• Consider non-pharmacologic interventions: compression stockings, adequate salt/fluid intake if not volume-overloaded 1

Chronic Kidney Disease

• Modest increases in creatinine (up to 30% above baseline) are acceptable and should not prompt discontinuation of ACE-I/ARB/ARNI 1
• More frequent monitoring needed in patients with baseline eGFR <60 mL/min/1.73 m² 1

Hyperkalemia

• Use potassium binders (e.g., patiromer) rather than discontinuing life-saving MRA therapy 1
• ARNI actually reduces hyperkalemia risk compared to ACE-I plus MRA 1

Hospitalized Patients

• Continue GDMT except when hemodynamically unstable or contraindicated 1
• Initiate GDMT after ≥24 hours of stabilization with adequate organ perfusion 1
• In-hospital initiation substantially improves post-discharge medication use compared to deferring to outpatient setting 1

Adjunctive Therapies for Specific Populations

Ivabradine

• Add ivabradine (start 5 mg twice daily; target 7.5 mg twice daily) only if patient is in sinus rhythm with NYHA class II-III symptoms, resting heart rate ≥70 bpm, and on maximally tolerated beta-blocker 1
• Only 25% of participants in ivabradine trials were on optimal beta-blocker doses, emphasizing that beta-blocker uptitration must precede ivabradine 1

Hydralazine/Isosorbide Dinitrate

• Add hydralazine 25 mg three times daily plus isosorbide dinitrate 20 mg three times daily (target 75 mg/40 mg three times daily) for self-identified Black patients with NYHA class III-IV symptoms despite optimal quadruple therapy 3, 1

Device Therapy Considerations

• Cardiac resynchronization therapy (CRT) is recommended for symptomatic HFrEF patients in sinus rhythm with QRS duration ≥150 msec and left bundle branch block morphology with LVEF ≤35% despite optimal medical therapy 2
• Implantable cardioverter-defibrillator (ICD) is indicated for patients with symptomatic HF (NYHA Class II-III) and LVEF ≤35% despite ≥3 months of optimal medical therapy who are expected to survive >1 year with good functional status 2

Critical Medications to Avoid

• Never combine ACE inhibitor with ARNI (risk of angioedema) 1
• Never use triple combination of ACE inhibitor + ARB + MRA (extreme hyperkalemia and renal dysfunction risk) 1
• Avoid diltiazem or verapamil in HFrEF as they increase risk of worsening heart failure and hospitalization 2
• Avoid non-evidence-based beta-blockers (e.g., metoprolol tartrate, atenolol); only carvedilol, metoprolol succinate, and bisoprolol reduce mortality 1, 2

Common Pitfalls to Avoid

• Delaying initiation of all four medication classes simultaneously 1
• Accepting suboptimal doses without aggressive uptitration to target doses 3, 1
• Stopping medications for asymptomatic hypotension with adequate perfusion 1
• Overreacting to modest creatinine elevation (up to 30% above baseline is acceptable) 1
• Using metoprolol tartrate instead of metoprolol succinate 1, 2
• Inadequate monitoring of blood pressure, renal function, and electrolytes during uptitration 1

Monitoring Requirements

• Schedule early outpatient follow-up within 7-14 days after any medication change 1
• Assess volume status, blood pressure, renal function, and electrolytes at each visit 1
• More frequent monitoring required in elderly patients (≥65 years) and those with chronic kidney disease 1
• Serial natriuretic peptide levels can guide diuretic titration 1

Expected Outcomes

• Quadruple therapy reduces all-cause mortality by 61% (HR 0.39,95% CI 0.32-0.49) and adds approximately 5.3 life-years per patient compared to no treatment 1
• Transitioning from traditional dual therapy (ACE-I and beta-blocker) to quadruple therapy extends life expectancy by approximately 6 years 1
• Benefits are maintained across all baseline systolic blood pressure levels, including patients with SBP <110 mmHg 1